MuReva Phototherapy gains investment from the Angel Physicians Fund and adds Manish Bhandari, MD, E-MBA to Board of Directors
MuReva Phototherapy has announced that the Angel Physicians Fund has made an investment in the company and in conjunction with this investment, Manish Bhandari, MD, E-MBA will join the company’s Board of Directors. MuReva plans to utilize this funding to continue the development of the company’s photobiomodulation therapy device to treat radiation and chemotherapy induced mucositis.
The Angel Physicians Fund is a seed stage investor group of physicians and healthcare entrepreneurs exclusively focused on life science and healthcare investments. Their mission is to bring more clinical tools to the marketplace, while attaining superior returns for their investors. The fund is comprised of clinicians, investigators, innovators, healthcare entrepreneurs and executives with a collective skill set that brings value to the healthcare startups they support.
Dr. Manish Bhandari is a Managing Partner of the Angel Physicians Fund and has spent his entire career in healthcare, including over 15 years as a practicing medical oncologist. Dr. Bhandari received his medical education at Harvard Medical School, Boston and Oncology training at UCLA and University of Michigan-Ann Arbor. He has been an Echoing Green and Albert Schweitzer fellow, as well as received awards from American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). Dr. Bhandari obtained an executive MBA working with McKinsey & Company as a health care strategy consultant. He subsequently headed the health-care services division at CVS, a Fortune-100 company, where helped launch the company’s specialty pharmacy/PBM business.